Immune interception represents an exciting opportunity to stop cancer in its tracks
Data from two studies suggest a good rationale for targeting T-cell dysfunction with precision immunotherapy to intercept pre-cancerous lesions
Are we close to personalise immunotherapy?
According to the 2024 ESMO Immuno-Oncology Awardee, Ton Schumacher, tackling the T-cell receptor challenge with vast datasets and cutting-edge high-throughput methods may pave the way for advances in the field
Tumour-agnostic oncology – time has come to re-think clinical research
Advances in precision oncology are moving the field towards a biology-based cancer care, and ESMO is supporting the change with a series of tailored resources for medical oncologists
Challenges in cell-based immunotherapies create opportunities for progress
According to the 2023 ESMO Immuno-Oncology Awardee, Steven A. Rosenberg, the keys to progress are identifying the optimal characteristics of antitumour effector lymphocytes, cancer antigen identification and strategies for overcoming resistance mechanisms to enhance immune-cell function
Updated hallmarks of cancer guide treatment development
Old and emerging traits of cancer provide a common set of principles that may help research shape future progress
TIL therapy – an opportunity for a few centres?
Regulatory, practical and economic challenges are associated with implementing this personalised treatment on a larger scale, thus currently limiting its availability and accessibility to patients
Exploiting knowledge of neutrophil protumour and antitumour phenotypes to treat cancer
Identifying the trigger that switches neutrophils from protumour to antitumour activity in the tumour microenvironment could open the door to new therapeutic options
Encouraging results validate PARP7 and TGFβ1 as potential targets for immunotherapy
Safety and biomarker status data of the PARP7 inhibitor RBN-2397 and the IgG4 monoclonal antibody SRK-181 presented at the ESMO TAT Congress 2023
Predict the next evolutionary move of cancer: a feasible winning strategy?
Tumour evolution is one of the primary reasons for resistance to treatment and researchers are now learning how to use it to lead tumours down a dead end